Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) – Pipeline Review, H2 2018

Global Markets Direct’s, ‘Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) – Pipeline Review, H2 2018’, provides in depth analysis on Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Immunology, Dermatology, Respiratory, Cardiovascular, Central Nervous System, Gastrointestinal, Hematological Disorders, Metabolic Disorders, Musculoskeletal Disorders and Ophthalmology under development targeting Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2)

– The report reviews Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects

– The report assesses Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Aerie Pharmaceuticals Inc

AstraZeneca Plc

Bristol-Myers Squibb Co

Celgene Corp

Celon Pharma SA

CJ HealthCare Corp

Concert Pharmaceuticals Inc

CTI BioPharma Corp

Eli Lilly and Co

Incyte Corp

Japan Tobacco Inc

NMS Group SpA

Novartis AG

NS Pharma Inc

Simcere Pharmaceutical Group

Theravance Biopharma Inc

Tragara Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC

2.7.10.2) Overview

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC

2.7.10.2) Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC

2.7.10.2) Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC

2.7.10.2) Companies Involved in Therapeutics Development

Aerie Pharmaceuticals Inc

AstraZeneca Plc

Bristol-Myers Squibb Co

Celgene Corp

Celon Pharma SA

CJ HealthCare Corp

Concert Pharmaceuticals Inc

CTI BioPharma Corp

Eli Lilly and Co

Incyte Corp

Japan Tobacco Inc

NMS Group SpA

Novartis AG

NS Pharma Inc

Simcere Pharmaceutical Group

Theravance Biopharma Inc

Tragara Pharmaceuticals Inc

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC

2.7.10.2) Drug Profiles

APL-581 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AR-13503 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZD-1480 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

baricitinib Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CHZ-868 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CJ-15314 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CPL-407105 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CTP-543 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

delgocitinib Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fedratinib Drug Profile

Product Description

Mechanism Of Action

R&D Progress

jaktinib Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MA-2014 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NMSP-113 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NS-018 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OMT-001 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pacritinib Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ruxolitinib phosphate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAR-317461 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit JAK2 for Leukemia Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit JAK2 and JAK3 for Immunology and Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit JAK2 for Myeloproliferative Disorders Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TD-1473 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TG-02 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC

2.7.10.2) Dormant Products

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC

2.7.10.2) Discontinued Products

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC

2.7.10.2) Product Development Milestones

Featured News & Press Releases

Nov 01, 2018: Incyte provides data on ruxolitinib (Jakafi) at the 60th Annual ASH meeting

Nov 01, 2018: With availability of Olumiant (baricitinib), Lilly brings new oral treatment option for Canadians living with rheumatoid arthritis

Oct 25, 2018: FDA grants priority review for Ruxolitinib (Jakafi) as a treatment for patients with acute graft-versus-host disease

Oct 22, 2018: Theravance Biopharma reports data from TD-1473 phase 1b four-week study in oral late-breaker presentation at UEG Week 2018

Oct 15, 2018: New data showcasing Lilly's growing commitment in Rheumatology to be featured at the ACR/ARHP Annual Meeting

Oct 10, 2018: Theravance Biopharma Announces Data from Phase 1b Study of TD-1473 Selected for Oral Late-Breaker Presentation at UEG Week 2018

Oct 01, 2018: CTI BioPharma announces the continuation of PAC203 Study following interim data review

Sep 28, 2018: Concert revises Phase lla trial design to add new CTP-543 dose

Sep 13, 2018: Incyte announces positive data from phase 2b trial of Ruxolitinib cream in patients with atopic dermatitis

Sep 10, 2018: Lilly to Showcase Olumiant new data at the 27th European Academy of Dermatology and Venereology (EADV) Congress, furthering innovation for patients with complex dermatological conditions

Jul 19, 2018: Study Published in The Lancet Shows Benefit of Baricitinib 4 mg for the Treatment of Systemic Lupus Erythematosus (SLE)

Jul 18, 2018: CTI BioPharma Announces Pacritinib Program Update Following Type B Meeting with U.S. FDA

Jul 02, 2018: CTI BioPharma Announces the Continuation without Modification of PAC203 Phase 2 Study of Pacritinib in Patients with Myelofibrosis Previously Treated with Ruxolitinib

Jun 21, 2018: Incyte Announces REACH1 Pivotal Trial Meets Primary Endpoint of Overall Response Rate for Ruxolitinib (Jakafi) in Steroid-Refractory Acute Graft-Versus-Host Disease

Jun 21, 2018: Incyte to Present Data on Jakafi at 2018 Investor and Analyst Event

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indications, H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Companies, H2 2018 (Contd..3), H2 2018

Products under Development by Companies, H2 2018 (Contd..4), H2 2018

Number of Products under Investigation by Universities/Institutes, H2 2018

Products under Investigation by Universities/Institutes, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by Aerie Pharmaceuticals Inc, H2 2018

Pipeline by AstraZeneca Plc, H2 2018

Pipeline by Bristol-Myers Squibb Co, H2 2018

Pipeline by Celgene Corp, H2 2018

Pipeline by Celon Pharma SA, H2 2018

Pipeline by CJ HealthCare Corp, H2 2018

Pipeline by Concert Pharmaceuticals Inc, H2 2018

Pipeline by CTI BioPharma Corp, H2 2018

Pipeline by Eli Lilly and Co, H2 2018

Pipeline by Incyte Corp, H2 2018

Pipeline by Japan Tobacco Inc, H2 2018

Pipeline by NMS Group SpA, H2 2018

Pipeline by Novartis AG, H2 2018

Pipeline by NS Pharma Inc, H2 2018

Pipeline by Simcere Pharmaceutical Group, H2 2018

Pipeline by Theravance Biopharma Inc, H2 2018

Pipeline by Tragara Pharmaceuticals Inc, H2 2018

Dormant Products, H2 2018

Dormant Products, H2 2018 (Contd..1), H2 2018

Dormant Products, H2 2018 (Contd..2), H2 2018

Dormant Products, H2 2018 (Contd..3), H2 2018

Dormant Products, H2 2018 (Contd..4), H2 2018

Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2960

Saved reports